US 11,944,618 B2
Subcutaneous delivery of polymer conjugates of therapeutic agents
Randall Moreadith, Huntsville, AL (US); Kunsang Yoon, Madison, AL (US); Zhihao Fang, Madison, AL (US); Rebecca Weimer, Huntsville, AL (US); Bekir Dizman, Huntsville, AL (US); Tacey Viegas, Madison, AL (US); and Michael David Bentley, Huntsville, AL (US)
Assigned to Serina Therapeutics, Inc., Huntsville, AL (US)
Filed by Serina Therapeutics, Inc., Huntsville, AL (US)
Filed on Apr. 11, 2022, as Appl. No. 17/717,666.
Application 17/717,666 is a continuation of application No. 16/588,761, filed on Sep. 30, 2019, granted, now 11,298,350.
Application 16/588,761 is a continuation of application No. 15/480,122, filed on Apr. 5, 2017, granted, now 10,426,768, issued on Oct. 1, 2019.
Application 15/480,122 is a continuation of application No. 14/355,515, abandoned, previously published as PCT/US2012/063088, filed on Nov. 1, 2012.
Application 14/355,515 is a continuation in part of application No. 13/524,994, filed on Jun. 15, 2012, granted, now 8,383,093, issued on Feb. 26, 2013.
Claims priority of provisional application 61/554,336, filed on Nov. 1, 2011.
Prior Publication US 2022/0354841 A1, Nov. 10, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4745 (2006.01); A61K 9/00 (2006.01); A61K 31/381 (2006.01); A61K 31/4045 (2006.01); A61K 31/4462 (2006.01); A61K 31/4535 (2006.01); A61K 31/7048 (2006.01); A61K 47/54 (2017.01); A61K 47/60 (2017.01); A61K 47/61 (2017.01)
CPC A61K 31/4745 (2013.01) [A61K 9/0019 (2013.01); A61K 31/381 (2013.01); A61K 31/4045 (2013.01); A61K 31/4462 (2013.01); A61K 31/4535 (2013.01); A61K 31/7048 (2013.01); A61K 47/542 (2017.08); A61K 47/60 (2017.08); A61K 47/61 (2017.08)] 13 Claims
 
1. A method for treating a disease or condition related to dopamine insufficiency in the peripheral or central nervous system in a subject, the method comprising the step of administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a poly(oxazoline) polymer conjugate comprising a water soluble poly(oxazoline) polymer and an agent, wherein a release profile of the agent is selectable based on the selection of the poly(oxazoline) polymer conjugate, the poly(oxazoline) polymer conjugate having the structure:

OG Complex Work Unit Chemistry
wherein
L is

OG Complex Work Unit Chemistry
R3 forms a linkage with the poly(oxazoline) polymer;
R4 is —CH2—C(O)—O—, —CH(CH3)—C(O)—O—, —CH2—CH2—C(O)—O—, —CH2—CH2—CH2—C(O)—O—, —CH2—O—C(O)—, —CH2(CH3)—O—C(O)—, —CH2—CH2—O—C(O)— or —CH2—CH2—CH2—O—C(O)—;
R is an initiating group;
R1 is a non-reactive group;
A is the agent, and wherein A is selected from the group consisting of a dopamine agonist, dopamine antagonist, an adenosine A2A antagonist, an anticholinergic, a monamine oxidase-B inhibitor or a catechol-O-methyl transferase inhibitor;
a is ran which indicates a random copolymer or block which indicates a block copolymer;
o is from 1-50;
m is from 1-1000; and
T is a terminating group, wherein the release profile is dependent on the selection of R4.